$OTTR

Otter Tail Corp (OTTR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Otter Tail Corp (OTTR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Thomas J. Webb notified Otter Tail Corporation (the “Company”) of his intention to not stand for reelec

Original reporting
Published Sep 1, 2026, 1:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 2:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$OTTR
Neutral
high confidence
Mentioned
$OTTR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$OTTRNeutralLow
01

Why it matters

The filing is a routine corporate governance update with no disclosed financial impact.

02

Market read

Low relevance; primarily a governance disclosure.

03

What to watch

Potential hidden succession planning or upcoming board re‑composition that may affect future governance.

Relevance 6/10Novelty 3/10Timing: filed Sep 1 2026

Background

Otter Tail Corp filed a Form 8‑K under Item 5.02 to disclose director retirements per its retirement policy.

Company-level read

Ticker impact

$OTTRNeutralHigh confidence
Context

OTTR filed an 8‑K announcing the retirement of directors Thomas J. Webb and Kathryn O. Johnson.

Expected impact

minimal or no immediate price change

Evidence & confidence

The filing contains only routine governance changes with no operational or financial impact disclosed.

Market effects

None; governance change does not affect the utilities sector broadly.

Limited to Otter Tail Corp shareholders.

None

Counterpoint

If the board turnover signals upcoming strategic shifts, the stock could react positively.

Key entities

  • Otter Tail Corp

    Utility holding company filing the 8‑K.

  • Thomas J. Webb

    Retiring director.

  • Kathryn O. Johnson

    Retiring director.

Related articles

$OTTRMedAI 8/10

Otter Tail (OTTR) Q2 2026 Earnings Call Transcript

Otter Tail Corporation (OTTR) reported Q2 2026 adjusted diluted EPS of $1.66, down 10% from $1.85, and a $103.5 million pre-tax antitrust litigation settlement charge. Full-year 2026 adjusted EPS guidance was raised to $5.68 to $6.08. Electric revenue fell to $121.3 million; Plastics adjusted net income declined to $47.1 million. The company outlined a $1.9 billion five-year capital plan and reaffirmed 7% to 9% long-term earnings growth.

$OTTRMed

Otter Tail Q2 Earnings Call Highlights

Otter Tail (NASDAQ:OTTR) reported Q2 adjusted results that beat expectations and raised plastics guidance, citing revised pricing assumptions and sequentially higher PVC pipe prices. The company reached a preliminary settlement in U.S. PVC antitrust litigation, agreeing to pay $103.5 million pending final court approval. Otter Tail also expanded utility projects and raised manufacturing guidance.

$OTTRHigh

Otter Tail Corp (OTTR): Results of Operations and Financial Condition

Otter Tail Corp (OTTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Press Release August 3, 2026 Otter Tail Corporation Announces Second Quarter Results and Updates Annual Earnings Guidance FERGUS FALLS, Minnesota - Otter Tail Corporation (Nasdaq: OTTR) today announced financial results for the quarter ended June 30, 2026. SUMMARY • Reported quar

$JAZZHighAI 8/10

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals (JAZZ) targets $5B opportunity for zanidatamab, with oncology revenue exceeding $1B. The company expects strong adoption of the triplet regimen and sees limited near-term competition. Jazz also reported 40% growth for Zepzelca and strong early adoption for Modeyso. The company generated $824M cash in H1 and raised $1B through a convertible offering, with plans for further investments and acquisitions.

$AMZNMedAI 9/10

Amazon (AMZN)’s Debut Sterling Bond Sale Prices Bigger, But Demand Cools from Alphabet’s

Amazon (AMZN) raised £4.25B ($5.76B) in its first sterling bond sale, exceeding initial expectations but seeing lower demand than Alphabet's recent offering. The four-tranche deal spans 3 to 19 years, with demand at 2.5 times the amount raised. Analysts note potential cooling in investor appetite for hyperscaler debt. Proceeds may support AWS growth and AI infrastructure investments, though rising debt and financing costs pose risks.